Modality
mAb
MOA
JAK1/2i
Target
CFTR
Pathway
NF-κB
PSP
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
Phase 2Current
NCT03288970
2,202 pts·PSP
2024-06→TBD·Not yet recruiting
2,202 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-146mo agoConference· PSP
Trial Timeline
Q3Q42025Q2Q3Q4
P2
Not yet…
Catalysts
Conference
2025-10-14 · 6mo ago
PSP
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03288970 | Phase 2 | PSP | Not yet recr... | 2202 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |